A recent study conducted by Trudell Medical International (TMI) demonstrated the effectiveness of the company’s Aerobika OPEP medical device in the treatment of Chronic Obstructive Pulmonary Disease (COPD), a condition that affects about 250 million people in the world. The data of the study was presented at the 2014 European Respiratory Society (ERS) Conference, in Munich, Germany.
The Aerobika is a non-drug therapy, hand-held device with a pressure-oscillation dynamic that works through exhalation, which creates positive pressure and oscillations, enabling mucus clearance as well as potency in the airways. There is currently no drug treatment designed for mucus clearance, and many COPD patients suffer from excessive mucus, which can cause difficulties in breathing, inability to conduct everyday activities, and decreased quality of life.
“The results from this study provide compelling evidence that patients suffering from COPD or Bronchiectasis now have a safe and easy-to-use method to address the unmet need of mucus clearance and improve their quality of life,” explained the group director of Science and Technology at TMI, Dr. Jason Suggett. “We are also excited about the future possibility of looking at the longer term impact on patient outcomes and healthcare system efficiencies.”